Why the study?
Do first-line antihypertensive therapies reduce major disease endpoints compared to placebo in hypertensive patients?
Population
Hypertensive patients evaluated in 18 long-term randomized trials and observational studies
Comparison
First-line antihypertensive therapies vs Placebo
Design
Meta-analysis
Follow-up
long-term
Authors
Loading...
Supports low-dose diuretics as first-line antihypertensives; confirms major cardiovascular event reduction versus placebo.
Do first-line antihypertensive therapies reduce major disease endpoints compared to placebo in hypertensive patients?
Low-dose diuretics and beta-blockers effectively prevent major cardiovascular events in hypertension, supporting their use as first-line agents, whereas evidence for calcium channel blockers and ACE inhibitors is currently lacking.
Bruce M. Psaty (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: